Phil Raess, M.D., Ph.D.

  • Associate Professor of Pathology & Laboratory Medicine, School of Medicine
  • Program Director, Hematopathology Fellowship
  • Medical Director, Immunohistochemistry Lab


  • B.S., 2001, Indiana University
  • M.D., Ph.D., 2009, University of Wisconsin
  • Residency:

    • Anatomic and Clinical Pathology, Hospital of the University of Pennsylvania, 2009-2013
  • Fellowship:

    • Surgical Pathology, Oregon Health & Science University, Portland, Oregon, 2013-2014
    • Hematopathology, Oregon Health & Science University, Portland, Oregon, 2014-2015
  • Certifications:

    • Anatomic and Clinical Pathology (American Board of Pathology), 2013
    • Hematopathology (American Board of Pathology), 2015

Areas of interest

  • Clinical interests: Molecular pathology, hematopathology, and digital pathology
  • Research interests: The pathogenesis of various types of lymphoma, the effect of molecular events on tumor phenotype and prognosis, and development of novel diagnostic approaches for challenging hematopathology cases.


Selected publications

  • Select publications (full PubMed bibliography link in Additional Information) 
  • In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. Anekpuritanang T, Klairmont MM, Gradowski J, Hagiwara K, Bailey NG, Chandra PK, Liu Y, Mulder HL, Easton J, Zhang J, Martin MG, Owczarczyk AB, Dunlap J, Fan G, Press RD, Raess PW. Blood Adv.
  • Molecular Discordance between Myeloid Sarcomas and Concurrent Bone Marrows Occurs in Actionable Genes and Is Associated with Worse Overall Survival.Werstein B, Dunlap J, Cascio MJ, Ohgami RS, Fan G, Press R, Raess PW. J Mol Diagn.
  • MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. Raess PW, Moore SR, Cascio MJ, Dunlap J, Fan G, Gatter K, Olson SB, Braziel RM. Leukemia & Lymphoma. 2018 Jun. PMID: 28868942.